Other languages PMV Pharmaceuticals, Inc.

Equities

PMVP

US69353Y1038

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-30 EDT			5-day change	1st Jan Change
1.8 ^USD	+1.69%		-0.28%	-41.94%

04-12	Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target	MT
03-27	PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	03-27
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer	03-18
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29
PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%	01-18
MORNING BRIEFING - USA/Asien	01-08
PMV Pharmaceuticals, Inc. Announces Executive Changes	01-05
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
PMV Pharmaceuticals Says Updated Trial Data Show Cancer Therapy Induces Anti-Tumor Activity; Shares Fall	23-10-12
PMV Pharmaceuticals, Inc. Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types with TP53 Y220C Mutation	23-10-12
PMV Pharmaceuticals, Inc. to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	23-09-20
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10
PMV Pharmaceuticals Proposes $200 Million Mixed Shelf Offering	23-03-02
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08
PMV Pharmaceuticals, Inc. Announces Board Changes	22-11-04
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09
PMV Pharmaceuticals to Collaborate with Merck in Clinical Trial	22-07-18
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors	22-07-18
PMV Pharmaceuticals Shares Fall After Early Trial Data on PC14586	22-06-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages PMV Pharmaceuticals, Inc.

Equities

PMVP

US69353Y1038

Other languages

Filters